Hypercholesterolemia-induced vascular disease and atherosclerosis are characterized by a decrease in the bioavailability of endothelium-derived nitric oxide. Endothelial nitric-oxide synthase (eNOS) associates with caveolae and is directly regulated by the caveola protein, caveolin. In the present study, we examined the effects of oxidized low density lipoprotein (oxLDL) on the subcellular location of eNOS, on eNOS activation, and on caveola cholesterol in endothelial cells. We found that treatment with 10 g/ml oxLDL for 60 min caused greater than 90% of eNOS and caveolin to leave caveolae. Treatment with oxLDL also inhibited acetylcholine-induced activation of eNOS but not prostacyclin production. oxLDL did not affect total cellular eNOS abundance. Oxidized LDL also did not affect the palmitoylation, myristoylation or phosphorylation of eNOS. Oxidized LDL, but not native LDL, or HDL depleted caveolae of cholesterol by serving as an acceptor for cholesterol. Cyclodextrin also depleted caveolae of cholesterol and caused eNOS and caveolin to translocate from caveolae. Furthermore, removal of oxLDL allowed eNOS and caveolin to return to caveolae. We conclude that oxLDL-induced depletion of caveola cholesterol causes eNOS to leave caveolae and inhibits acetylcholine-induced activation of the enzyme. This process may be an important mechanism in the early pathogenesis of atherosclerosis.
Studies in animal models and in humans have shown that hypercholesterolemia-induced vascular disease and atherosclerosis are characterized by an early, selective impairment of endothelium-derived relaxation. This impairment is due to a decrease in bioavailable endothelium-derived nitric oxide (NO) 1 (1) . In the initial phase of the disease process, there is impaired responsiveness to receptor-dependent stimuli, such as acetylcholine, whereas responsiveness to receptor-independent stimuli such as the calcium ionophore A23187 is not altered. As such, the early pathogenesis involves attenuated endothelial NO production in response to extracellular stimuli, but the capacity for maximal enzyme activation and the breakdown of NO are not affected. As the disease progresses, there is nonspecific inhibition of NO bioavailability. Although this later inhibition is most likely multifactorial in origin, it is at least partly due to enhanced inactivation of NO by superoxide anions (2) (3) (4) . These processes result in increased neutrophil adherence to the endothelium, thereby promoting a key step in the pathogenesis of atherosclerosis (5) . The chronic inhibition of NO synthesis in rabbit models of hypercholesterolemia accelerates the development of vascular dysfunction and intimal lesions, providing additional evidence that the impairment of NO synthesis promotes atherogenesis (6) . In vitro investigations have further shown that oxidized LDL (oxLDL) inhibits NO-mediated responses. Antioxidants reduce both the formation of free radicals and the oxidative modification of LDL that lead to impaired NO-related responses (7) . Thus, NO is critically involved in the pathogenesis of atherosclerosis, and the initiating events are characterized by attenuated endothelial NO production in response to extracellular stimuli. A family of nitric-oxide synthases (NOS) are responsible for NO synthesis (8) . Inducible NOS and neuronal NOS are primarily cytosolic enzymes, whereas the constitutive or endothelial NOS (eNOS) is primarily membrane-bound (8) . Endothelial NOS is both myristoylated and palmitoylated (9, 10) . The acylation of eNOS is responsible, in part, for its association with membranes (9, 10). Shaul et al. (9) demonstrated that eNOS targets to plasmalemmal caveolae and that the targeting is dependent on the acylation of eNOS. Michel et al. (11) reported that the caveola protein, caveolin, directly binds eNOS, thereby regulating the generation of NO. Interestingly, Sessa and colleagues (12, 13) demonstrated that eNOS also associates with Golgi membranes in an acylation-dependent manner. The biological function of Golgi-localized eNOS and the relationship between Golgi and caveola pools of the enzyme has not been explored.
The caveola microdomains to which eNOS is targeted are found in most cells. Caveolae are highly enriched in cholesterol, sphingomyelin, glycolipids, and known signal transducing molecules (14 -16) . Caveolae contain complete signaling complexes from extracellular receptors to intracellular effector systems. For instance, caveolae are enriched with the following (for a review, see Ref. 17) : heterotrimeric GTP binding proteins; protein kinase C; receptors for endothelin 1 and acetylcholine; an ATP-dependent Ca 2ϩ pump and a form of the inositol 1,4,5-triphosphate-sensitive Ca 2ϩ channel; and the small GTP-bind-ing protein Ras. Recent studies further indicate that caveolae play a role not only in the compartmentalization of signaling molecules, but also in the modulation and integration of various responses to extracellular stimuli (11, 18, 19) .
In the present study, we hypothesized that oxLDL inhibits eNOS activation by disrupting the association of eNOS with caveolae. We examined the effects of oxLDL on the subcellular location of eNOS, eNOS activation, and caveola cholesterol. The present study demonstrates that oxLDL depletes caveolae of cholesterol and causes eNOS to translocate from the plasma membrane. In addition, oxLDL inhibits the ability of acetylcholine to efficiently activate the enzyme.
EXPERIMENTAL PROCEDURES
Materials-M199, BME vitamin mix, fetal bovine serum, glutamine, trypsin-EDTA, OptiPrep, endothelial SFM growth medium, and penicillin/streptomycin were from Life Technologies, Inc. The BME amino acid mix, Percoll, and fluorescently labeled 2°antibodies were from Sigma. The analytical silica gel thin layer chromatography plates, heptane, petroleum ether, ethyl ether, acetic acid, and 2-propanol were from Fisher. The lipid standards (cholesterol, sphingomyelin, phosphatidylserine, phosphatidylinositol, phosphatidylcholine, and phosphatidylethanolamine) were from Supelco (Bellefonte, PA (20) .
Buffers-Sample buffer (5ϫ) consisted of 0.31 M Tris, pH 6.8, 2.5% (w/v) SDS, 50% (v/v) glycerol, and 0.125% (w/v) bromphenol blue. TBS consisted of 20 mM Tris, pH 7.6, and 137 mM NaCl. Blotting buffer consisted of TBS plus 0.5% Tween 20 and 5% dry milk. Wash buffer consisted of TBS plus 0.5% Tween 20 and 0.2% dry milk. Tris-saline consisted of 50 mM Tris (pH 7.4), 150 mM NaCl.
Cell Culture-Low passage (Ͻ5) porcine pulmonary artery endothelial cells were kindly provided by Dr. Bernhard Hennig (University of Kentucky). The cells were cultured in a monolayer and plated in a standard format. On day 0, approximately 5 ϫ 10 5 cells were seeded into 100-mm dishes with 10 ml of M199 medium supplemented with 100 units/ml penicillin/streptomycin, 0.5% (v/v) L-glutamine, BME vitamin mix (1 ml/100 ml of M199), BME amino acid mix (1 ml/100 ml of M199), and 10% (v/v) fetal bovine serum. The cells were used on day 6. To radiolabel endogenous lipids, the medium on day 5 was changed to M199 plus 20 mM HEPES (pH 7.4), adding [ 3 H]acetate (30 Ci/dish), and incubating for 18 h at 37°C.
Isolation, Labeling, and Oxidation of Lipoproteins-LDL (d ϭ 1.019 -1.05 g/ml) and HDL (d ϭ 1.063-1.21 g/ml) were isolated from fresh human plasma by density gradient ultracentrifugation as described previously (21, 22) . The HDL 3 subfraction (d ϭ 1.13-1.18 g/ml) was isolated from other HDL subfractions using a density gradient fractionator (ISCO). The HDL 3 subfraction was used for all of the experimental treatments described herein. The purity of each lipoprotein fraction was assayed by SDS-PAGE and Coomassie staining. [ 3 H]cholesteryl linoleate was incorporated into LDL as described previously (23) . The specific activity of [ 3 H]cholesteryl linoleate-LDL ranged from 32 to 58 dpm/ng of LDL protein. LDL apolipoproteins were iodinated by the iodine monochloride method (24) to a specific activity of 400 -600 cpm/ng LDL protein. Oxidized LDL was prepared by incubating fresh LDL with 10 M of CuSO 4 at 37°C for 16 h. The material was dialyzed against a sterile solution (150 mM NaCl, 1 mM EDTA, 100 g/ml polymyxin B, pH 7.4) and then sterilized by filtration. The cholesterol, triglyceride (25) , and protein (26) content of the lipoprotein was determined by standard methods. The homogeneity of each preparation was determined by SDS-PAGE. The extent of LDL oxidation was estimated by agarose gel electrophoresis and by measuring the amount of thiobarbituric acid reactive substances (TBARS) generated with a colorimetric assay for malondialdehyde (27) .
Isolation of Caveolae-Caveolae membranes were isolated as described previously (28, 29) . This procedure generates a highly purified plasma membrane microdomain that is free from intracellular markers and bulk plasma membrane markers. This method has been used extensively to characterize caveola membranes (9, 16, 29 -32).
Enzyme Assays-Galactosyl transferase, NADPH cytochrome c reductase, and alkaline phosphatase were assayed using methods adapted from Graham and Higgins (33) .
Electrophoresis and Immunoblots-The amount of protein in each subcellular fraction was determined by a Lowry assay (26) . SDS-PAGE and immunoblots were performed as described previously (28, 29) .
Indirect Immunofluorescence-Endothelial cells grown on glass coverslips were washed once with PBS and then incubated at 37°C in lipoprotein-deficient serum containing 20 mM HEPES (pH 7.4) and 10 g/ml oxLDL for 60 min. Control and oxLDL-treated cells were then washed in 0.1 M phosphate buffer (PB) and fixed for 10 min with 4% (w/v) paraformaldehyde in PB. After fixation, the cells were rinsed three times with PB, permeabilized with 0.1% Triton X-100 in PB for 2 min, and rinsed three times in PB. Cells were then incubated for 30 min in a 1°antibody mixture containing polyclonal antibody to caveolin and monoclonal antibody to eNOS made up in PB plus 1% bovine serum albumin. Cells were washed three time with PB and then incubated for 30 min in a 2°antibody mixture consisting of rhodamine isothiocyanategoat anti-rabbit IgG and fluorescein isothiocyanate-goat anti-mouse IgG made up in PB plus 1% bovine serum albumin. The concentration of individual antibodies in the mixtures was 20 g/ml. Cells were washed three times with PB and once in distilled water and mounted in Fluoromount G containing 2.5% 1,4-diazabicyclo-(2.2.2)octane as an anti-bleach agent. Cells were examined on a Nikon Eclipse E800 microscope, and fluorescence images were recorded using a Hamamatsu Orca CCD camera.
NOS Activity-NOS activation was determined in whole endothelial cells by measuring L-
]citrulline using methods previously described (34) . Subconfluent cells were preincubated in PBS for 60 min at 37°C. After the preincubation period, the incubation for NOS activity was initiated by aspirating the PBS from the wells and replacing it with 400 l of PBS containing 0.75 Ci/ml
3 H]arginine. The plates were incubated at 37°C for 15 min in the absence of exogenous stimulation (basal) or in the presence of varying concentrations of acetylcholine (10 Ϫ10 to 10 Ϫ4 M). The NOS reaction was terminated by adding 500 l of ice-cold 1 N trichloroacetic acid to each well. The preincubation and incubation were performed in the presence of either native LDL (nLDL) or oxLDL at a final concentration of 10 g/ml. The amount of L-[ 3 H]citrulline generated was measured as described (34) . In individual experiments performed in 24-well plates, four wells were used for each treatment group. Findings were confirmed in three independent experiments. NOS activation in the intact cells was completely inhibited by 2 mM nitro-L-arginine methyl ester. L-[
3 H]Arginine uptake was measured following nLDL or oxLDL pretreatment as done in the experiments evaluating eNOS localization and eNOS activation. Uptake was similar in nLDL-and oxLDL-treated cells.
NOS enzymatic activity in cell lysates and subcellular fractions was determined by measuring the conversion of [
H]arginine to [
3 H]citrulline in the presence of excess amounts of all required substrates and cofactors (34) .
Prostacyclin Radioimmunoassay-Cells were incubated for determinations of prostacyclin production using methods we have previously described (35) . Briefly, cells grown in 24-well plates were preincubated in RPMI 1640 medium containing either nLDL or oxLDL under the conditions used in the studies of eNOS localization and eNOS activation. Incubations for prostacyclin production were then performed over 15 min in the continued presence of nLDL or oxLDL. Basal (nonstimulated) prostacyclin production and that stimulated by 10 Ϫ5 M bradykinin or 10 Ϫ5 M acetylcholine were evaluated. Samples of incubation medium were assayed for the stable metabolite of prostacyclin, 6-ketoprostaglandin F 1␣ , by radioimmunoassay (35) . In all experiments, n ϭ 4 for each determination, and findings were replicated in three independent studies.
Palmitoylation (10, 36) . For the acylation experiments, the gels were soaked in 1 M Tris, pH 7.5, or 1 M hydroxylamine, pH 7.5, for 14 h before being processed for fluorography. Palmitoyl groups are attached by a thioester linkage and are susceptible to hydrolysis by hydroxylamine, whereas myristate is insensitive to hydroxylamine.
Immunoprecipitations-The immunoprecipitation studies were done as described previously (28, 29) .
Radiolabeled Lipid Determinations and Cholesterol Mass Measurements-Thin layer chromatography (28, 29) and cholesterol mass measurements were performed as described previously (37) .
RESULTS

Effects of oxLDL on eNOS and Caveolin Subcellular Location-
We first determined if oxLDL alters the subcellular distribution of eNOS. Porcine pulmonary artery endothelial (PPAE) cells were incubated with 100% human lipoproteindeficient serum (LPDS) containing 20 mM HEPES (pH 7.4) only or with 10 g/ml HDL, 10 g/ml nLDL, or 10 g/ml oxLDL (15-20 nmol/mg TBARS) for 1 h at 37°C before they were washed and subfractionated to isolate caveolae (28, 29) . Table  I demonstrates that the caveola fraction was not significantly contaminated with galactosyl transferase (Golgi) or NADPH cytochrome c reductase (endoplasmic reticulum) but contained a significant amount of the alkaline phosphatase (plasma membrane) activity. Equal amounts of protein from each subcellular fraction were analyzed for the presence of eNOS and caveolin by immunoblotting. Caveolae isolated from control cells (Fig.  1A , LPDS) and cells treated with nLDL or HDL (Fig. 1A , nLDL and HDL) were highly enriched in eNOS. Caveolin, a caveola marker protein, was also highly enriched in the caveola fraction (Fig. 1B, LPDS, nLDL, and HDL) . Dramatically, treatment with oxLDL induced eNOS and caveolin to move to the internal membrane fraction (Fig. 1, A and B) . The internal membrane fraction contains ER, Golgi, mitochondria, and numerous other intracellular organelles, so the exact location(s) of the eNOS and caveolin was not revealed. oxLDL treatment did not cause PKC␣ or GM 1 , which are additional molecules shown to be enriched in caveolae (38 -40) , to translocate out of caveolae (Fig. 1C) . In addition, the noncaveola protein, transferrin receptor, was excluded from the caveola fraction with all treatment conditions (Fig. 1C and data not shown) . Importantly, the same data were obtained when the cells were treated with the protein synthesis inhibitor, cycloheximide (50 g/ml) (data not shown). This indicates that oxLDL causes eNOS and caveolin to translocate to an intracellular membrane and that the presence of intracellular eNOS and caveolin is not due to de novo synthesis. In addition, the removal of oxLDL and continued incubation in the presence of cycloheximide (50 g/ml for 2 h) permitted eNOS and caveolin to return to the caveolae fraction (Fig. 1, A and B, Recovery) .
We used indirect immunofluorescence to confirm the subcellular fractionation data. PPAE cells were treated with LPDS, nLDL, or oxLDL as described above. The cells were co-labeled with anti-caveolin IgG (polyclonal) and anti-eNOS mAb (monoclonal). Fig. 2 shows that caveolin and eNOS co-localize at the plasma membrane in cells treated with LPDS and nLDL. However, oxLDL caused both caveolin and eNOS to translocate to an intracellular location. Caveolin and eNOS remain co-localized even after leaving the plasma membrane. These data confirm the redistribution of caveolin and eNOS in subcellular fractions shown in Fig. 1 . PPAE cells were treated with 100% LPDS containing 20 mM HEPES (pH 7.4) only or 10 g/ml HDL, 10 g/ml nLDL, or 10 g/ml oxLDL (15-20 nmol/mg TBARS) for 1 h at 37°C. After the incubation, selected dishes were washed and incubated for an additional 2 h in LPDS containing 20 mM HEPES (pH 7.4) only (Recovery). The cells were washed and processed to isolate caveolae by a standard procedure (28, 29) . An equal amount of protein (25 g) from each fraction was resolved by SDS-PAGE and immunoblotted with IgGs for eNOS (A) and caveolin (B). Signal for eNOS was evident at 135 kDa, and signal for caveolin was detected at 22 kDa. The immunoblots were developed by the method of chemiluminescence. The anti-eNOS immunoblots were exposed for 2 min, and the anti-caveolin immunoblots were exposed for 20 s. C, cells were treated with oxLDL as described above. An equal amount of protein (25 g) from each fraction was resolved by SDS-PAGE and immunoblotted with IgGs for PKC␣, GM 1 , and transferrin receptor. The anti-PKC␣, GM 1 , and transferrin immunoblots were exposed for 5 min. Shown are representative data from one of five independent experiments. PNS, postnuclear supernatant; CYTO, cytosol; IM, total intracellular membranes; PM, plasma membrane; CM, caveola membrane. Preliminary experiments demonstrated that incubation of cells with 10 g/ml of oxLDL for 60 min was required to maximally redistribute eNOS and caveolin (data not shown). 
a N.D. means that the level of enzymatic activity was below the sensitivity of the assay.
Effects of oxLDL on eNOS Activation-Because oxLDL induced the redistribution of eNOS, we tested the ability of acetylcholine to activate eNOS in intact cells exposed to oxLDL. NOS activity was determined in whole PPAE cells by using methods previously described (see "Experimental Procedures") (41) . This procedure provides a direct assessment of the acute activation of existing eNOS while keeping signal transduction mechanisms intact (34) . Treatment of cells with oxLDL (Fig. 3,  q) significantly reduced acetylcholine-stimulated eNOS activation compared with nLDL controls (Fig. 3, E) . Oxidized LDL suppressed the activation of eNOS at all concentrations of acetylcholine tested, resulting in a shift in the dose-response curve to the right by 100-fold. The value obtained when cells were incubated in LPDS (no added lipoproteins) and 10
3 H]citrulline/well. In addition, to rule out the possibility of nonspecific disruption of signaling pathways, we demonstrated that oxLDL treatment did not affect bradykinin-or acetylcholine-stimulated prostacyclin production (Table II) .
It was possible that the reduction in eNOS activation observed in Fig. 3 was because eNOS expression was downregulated. To test this, PPAE cells were treated with lipoproteins as above and then washed and lysed. NOS activity was determined in the whole cell lysates by measuring L-[ Effects of oxLDL on eNOS Modifications-Several laboratories have shown that acylation of eNOS, in part, controls its subcellular location (9, 12). To determine whether oxLDL induces the deacylation of eNOS, cells were radiolabeled with (Fig. 4A ) and myristoylation (Fig. 4B ) of eNOS are not affected by treatment with either nLDL or oxLDL. As anticipated, eNOS labeling with palmitate was sensitive to hydroxylamine, and eNOS labeling with myristate was insensitive to hydroxylamine.
Michel et al. (36) showed that phosphorylation of eNOS affects the localization of eNOS to the plasma membrane. To determine if oxLDL alters the phosphorylation of eNOS, PPAE cells were labeled with [ 32 P]orthophosphoric acid. Without removing the radiolabel, the cells were incubated with lipoproteins as described above, and eNOS IgG was used to immunoprecipitate eNOS from 100 g of cell lysates. The precipitates were resolved by SDS-PAGE, and radiolabeled proteins were detected and quantified with a PhosphorImager. As shown in Oxidized LDL but not nLDL induces eNOS and caveolin to co-localize in an internal membrane compartment. Cells were treated with 100% LPDS, 10 g/ml of nLDL, or 10 g/ml oxLDL (15-20 nmol/mg TBARS) in 100% LPDS containing 20 mM HEPES (pH 7.4) for 1 h at 37°C. After the incubation, the cells were fixed and processed for double label immunofluorescence to detect both caveolin and eNOS location in the same cells. Caveolin was visualized with a rhodamine isothiocyanate-goat anti-rabbit IgG, and eNOS was visualized with fluorescein isothiocyanate-goat anti-mouse IgG. Shown are representative data from one of four independent experiments.
FIG. 3.
Oxidized LDL decreases acetylcholine-induced activation of eNOS in intact cells. Subconfluent PPAE cells were placed in phosphate-buffered saline containing either nLDL or oxLDL at a final concentration of 10 g/ml for a 60-min preincubation at 37°C. After the preincubation period, the incubation for NOS activity was initiated by aspirating the PBS from the wells and replacing it with 400 l of PBS containing 0.75 Ci/ml L- 
TABLE II oxLDL does not inhibit receptor-mediated stimulation of
prostacyclin synthesis Cells were incubated for determinations of prostacyclin production using methods we have previously described (35) . In all experiments, n ϭ 4 for each determination, and findings were replicated in three independent studies. 
Redistribution of eNOS
hyperphosphorylation and cytosolic localization of eNOS. Because we did not detect any change in the phosphorylation of eNOS after treatment with oxLDL, we wanted to ensure that our assay system was appropriately sensitive. Therefore, we treated PPAE cells with 10 M bradykinin for 5 min at 37°C.
The cells were then lysed, immunoprecipitated, and processed as described above. Bradykinin caused an increase in the extent of eNOS phosphorylation (Fig. 4C, Bradykinin) . Quantification of eNOS phosphorylation from a series of immunoprecipitations (multiple protein concentrations) demonstrated that bradykinin induced a 3.5-fold increase in eNOS phosphorylation. Thus, our assay system was capable of detecting a change in eNOS phosphorylation. Effects of oxLDL on Caveola Cholesterol-The data presented thus far demonstrates that oxLDL inhibits acetylcholine-induced stimulation of eNOS and causes the redistribution of eNOS out of caveolae. Furthermore, oxidized LDL did not alter the postsecondary modification of eNOS (Fig. 4) . Caveola-associated cholesterol has been shown to be important in clustering glycosylphosphatidylinositol (GPI)-anchored proteins in caveolae (43) . We therefore determined if oxLDL alters the sterol content of caveolae. To test this, we radiolabeled PPAE cells with [ 3 H]acetate, washed extensively, and then incubated with nLDL or oxLDL. At the end of the incubation, the media containing the lipoproteins were collected and saved. The cells were then subfractionated to isolate caveolae. The amount of sterol in the caveola fractions and the extracellular media was then determined. Fig. 5A demonstrates that native LDL did not alter the amount of radiolabeled sterol associated with caveolae. However, radiolabeled sterol quantitatively transferred from caveolae to oxLDL in a time-dependent manner (Fig. 5B) . The relative amounts of sphingomyelin, phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine in the caveola fraction were not affected by any of the treatments (data not shown).
Although radiolabeled sterol transferred from caveolae to oxLDL, the above experiment does not determine if the caveolae are depleted of sterol. It is possible that the radiolabeled sterol in caveolae is exchanged for the cholesterol in the oxLDL. To test this, we treated the cells with oxLDL (Fig. 5C) or HDL (Fig. 5D) as described above and then directly measured the mass of cholesterol associated with the caveolae fractions. Cholesterol was quantified with a standard colorimetric enzyme assay (see "Experimental Procedures"). Fig. 5C demonstrates that treatment with oxLDL induces the complete loss of caveola-associated cholesterol. However, treatment with HDL did not alter the steady-state amount of sterol associated with caveolae (Fig. 5D) .
Although the caveola fraction was depleted of cholesterol in the presence of oxLDL, it is possible that oxidized sterols were transferred from the lipoprotein to caveolae and that this, rather than a depletion of cholesterol, was responsible for the translocation of eNOS and caveolin. To test this possibility, we labeled LDL with [ 3 H]cholesteryl linoleate prior to oxidation. The oxidized, radiolabeled LDL was then incubated with cells as described above. Of the 42,000 dpm added to cells, only 65 dpm were associated with the caveola fraction (background was 60 dpm, representative of three separate experiments). We also determined if oxLDL was internalized by measuring the degradation of 125 I-labeled oxLDL. Less than 1% of the 125 I was released after 60 min of incubation with the cells (representative of two experiments).
Effects of Cyclodextrin on eNOS and Caveolin Subcellular Location-The oxidized LDL-induced reduction of cholesterol levels in caveola appears to promote the translocation of eNOS out of caveolae. If the reduction in caveola-associated cholesterol was responsible for eNOS movement, then an independent method of decreasing caveola cholesterol should also induce eNOS redistribution. To test this, we treated PPAE cells with 5 mM ␤-trimethyl cyclodextrin for 1 h at 37°C prior to isolating caveolae. Cyclodextrin extracts cholesterol from caveolae (44). . Without removing the radiolabel, the cells were incubated with 100% LPDS containing 20 mM HEPES (pH 7.4) only or 10 g/ml nLDL or 10 g/ml oxLDL (15-20 nmol/mg TBARS) for 1 h at 37°C before washing and cell lysis. For A and B, equal amounts of cell lysates (100 g) were immunoprecipitated (duplicate sets) with eNOS IgG and resolved by SDS-PAGE. The gels were soaked in 1 M Tris, pH 7.5, or 1 M hydroxylamine, pH 7.5 for 14 h before being processed for fluorography. For C, 100 g of cell lysates were immunoprecipitated with eNOS IgG and resolved by SDS-PAGE. The radiolabeled eNOS was visualized with a PhosphorImager. In addition, one dish of PPAE cells labeled with [ 32 P]orthophosphoric acid was treated with 10 M bradykinin for 5 min at 37°C prior to processing. Shown are representative data from one of three independent experiments.
The isolated subcellular fractions were resolved by SDS-PAGE and analyzed by immunoblotting with IgGs for caveolin, eNOS, and PKC␣. In control cells, caveolin, eNOS, and PKC␣ were highly enriched in caveola fractions (Fig. 6, LPDS) . However, both caveolin and eNOS redistributed to the intracellular membrane fraction in the presence of cyclodextrin (Fig. 6 , Cyclodextrin), whereas PKC␣ remained enriched in the caveola fraction. When cyclodextrin was removed and the cells were allowed to recover for 2 h at 37°C in the presence of cycloheximide (50 g/ml), eNOS and caveolin returned to the caveola fractions (Fig. 6, Recovery) .
DISCUSSION
The present observations reveal that oxLDL has rapid and dramatic effects on eNOS localization and function. These findings provide a potential mechanism by which elevations in oxLDL rapidly attenuate the capacity for NO production by the endothelium. As such, they may at least partially explain the repeated observation in many experimental models and in humans that hypercholesterolemia-induced vascular disease and atherosclerosis are characterized by an early, selective impairment of agonist-stimulated endothelium-dependent relaxation and that this is due to a decrease in bioavailable endotheliumderived NO (1) .
Because of the emerging importance of caveolae in regulating eNOS activity, we determined if oxLDL alters the ability of eNOS to associate with caveolae. We demonstrated by two independent methods, subcellular fractionation ( Fig. 1 ) and indirect immunofluorescence (Fig. 2) , that oxLDL induces the redistribution of eNOS from caveolae to an internal membrane compartment. At present, we do not know the exact identity of the internal compartment. However, indirect immunofluorescence co-localization studies with Golgi and ER markers suggest that this internal membrane is not the Golgi or the ER (data not shown). Removal of oxLDL permitted eNOS to return to caveolae. Because the experiments were done in the presence of cycloheximide, the eNOS returning to caveolae was not the result of new protein synthesis. We did not observe a downregulation of eNOS as reported by Liao et al. (45) . However, our studies were done acutely (less than 2 h), whereas the studies by Liao et al. (45) required several days to down-regulate eNOS expression.
Studies by Michel and colleagues (18, 46) elegantly demonstrated that caveolin directly regulates eNOS activity. Caveolin binds eNOS and maintains the enzyme in an inactive state. Upon agonist stimulation, calcium-calmodulin binds to eNOS and promotes the dissociation of caveolin and the activation of eNOS. To determine the effects of oxLDL on the physiologic function of eNOS, studies of NOS activation in whole cells were performed. By measuring the conversion of L- were resolved by SDS-PAGE and analyzed by immunoblotting with IgGs for caveolin, eNOS, and PKC␣. The immunoblots were developed by the method of chemiluminescence. The anti-eNOS and anti-PKC␣ immunoblots were exposed for 3 min, and the anti-caveolin immunoblots were exposed for 15 s. Shown are representative data from one of four independent experiments. PNS, postnuclear supernatant; CYTO, cytosol; IM, total intracellular membranes; PM, plasma membrane; CM, caveola membrane.
presence of oxLDL compared with nLDL (Fig. 3) . In addition, eNOS activity stimulated by acetylcholine was attenuated in oxLDL-treated cells, with a shift of the dose-response curve downward and to the right. To achieve comparable responses, 100-fold greater concentrations of acetylcholine were required in oxLDL-versus nLDL-treated cells. These findings indicate that the capacity to activate eNOS is markedly attenuated by oxLDL. These findings are consistent with the attenuated capacity for NO production previously observed in cells transfected with myristoylation-deficient and/or palmitoylation-deficient eNOS mutants, which are not targeted to caveolae (9, 47, 48) . Importantly, basal prostacyclin production as well as bradykinin-and acetylcholine-stimulated prostacyclin production were similar in the presence of nLDL and oxLDL (Table  II) . Since the rapid stimulation of prostacyclin production by these agonists involves receptor-mediated calcium mobilization, these findings suggest that the signal transduction events required for acetylcholine-mediated NOS activation are not altered by oxLDL. Alternatively, the attenuated capacity for NOS activation with oxLDL exposure may be related to the intracellular relocalization of the enzyme. Taken collectively, these observations suggest that the localization of eNOS to caveolae is critical to normal endothelial cell function.
In the studies reported here, the majority of eNOS was associated with caveola membranes. Furthermore, we demonstrated that the isolated caveola fraction was not significantly contaminated with Golgi or endoplasmic reticulum (Table I) . However, numerous other studies have demonstrated that eNOS is also associated with the Golgi. In our experience, the source of the endothelial cells and the manner in which the cells are grown in vitro can dramatically affect the subcellular localization of eNOS (data not shown). Consistent with this, Michel and colleagues (10, 36) demonstrated that myristoylation, palmitoylation, and phosphorylation can all influence the localization of eNOS to caveolae. In contrast, Liu et al. (12) demonstrated that acylation targets eNOS to the Golgi. Surprisingly, oxLDL did not affect the steady-state acylation or phosphorylation of eNOS (Fig. 4 ). These findings demonstrate that additional mechanisms are also involved in controlling the subcellular location of eNOS.
Because the co-and post-translational processing of eNOS was not changed, we determined if oxLDL altered the lipid composition of caveolae. Oxidized LDL but not nLDL or HDL quantitatively depleted caveolae of cholesterol (Fig. 5 ). In contrast, oxidized LDL did not alter the relative amount of sphingomyelin or phospholipid associated with caveolae (data not shown). To test the possibility that the depletion of caveolaassociated cholesterol caused the redistribution of eNOS, we treated the cells with cyclodextrin. Cyclodextrin depletes the plasma membrane of cholesterol and has been previously used to disrupt caveolae (44) . Cyclodextrin also caused the redistribution of eNOS and caveolin but not the redistribution of PKC␣ (Fig. 6 ). These data suggest that caveola-associated cholesterol is essential for eNOS incorporation into caveolae. Another possibility is that oxysterols in oxLDL were incorporated into caveola membranes and that this was responsible for the translocation of eNOS and caveolin. This is unlikely, because cyclodextrin does not contain or generate oxysterols, yet eNOS and caveolin still moved out of caveolae with cyclodextrin treatment. Furthermore, when oxLDL was generated from LDL radiolabeled with cholesteryl linoleate, radiolabeled lipids were not transferred to caveola membranes. We also demonstrated that oxLDL was not internalized and degraded, thereby eliminating another possible mechanism.
There is a precedent for changes in cholesterol levels affecting the localization of proteins to caveolae. GPI-anchored proteins are enriched in caveolae and can be induced to further cluster in caveolae by cross-linking the proteins with ligand or antibodies (31). Anderson and colleagues (43, 49) convincingly demonstrated that the ability of a subset of GPI-anchored proteins to associate with caveolae depends on the cholesterol concentration of caveolae. The enrichment of alkaline phosphatase activity in caveolae (Table I) is because alkaline phosphatase is a GPI-anchored protein. Recent work by Varma and Mayor (50) and Friedrichson and Kurzchalia (51) further demonstrate the importance of cholesterol in maintaining GPIanchored protein clusters in microdomains.
In summary, we have shown that oxLDL promotes the redistribution of eNOS from caveolae to internal membrane sites by depleting caveolae of cholesterol. In addition, oxLDL inhibits the ability of acetylcholine to efficiently activate the enzyme. Further studies of the effects of oxLDL on eNOS trafficking will increase our fundamental knowledge of the regulation of endothelial NO production under both normal conditions and during altered cholesterol balance, thereby revealing the pathogenic link between hypercholesterolemia and endothelial dysfunction. It is anticipated that such work may lead to new preventative measures and treatment modalities for atherosclerosis that complement approaches aimed at cholesterol control.
